[8-K] iBio, Inc. Reports Material Event

Rhea-AI Filing Summary

iBio, Inc. filed a Form 8-K to announce that it has updated its corporate presentation. The new investor presentation is furnished as Exhibit 99.1 and is intended for use in meetings with investors, analysts and other stakeholders. The presentation includes forward-looking statements covered by “safe harbor” language under the Private Securities Litigation Reform Act of 1995. iBio notes it has no obligation to update the information in the presentation, although it may choose to do so through future public disclosures.

0001420720false00014207202025-11-172025-11-17

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): November 17, 2025

iBio, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction of incorporation)

​	​
001-35023	26-2797813
(Commission File Number)	(IRS Employer Identification No.)

​

11750 Sorrento Valley Road, Suite 200

San Diego, California 92121

(Address of principal executive offices and zip code)

(979) 446-0027

(Registrant’s telephone number including area code)

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐   Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​	​	​
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value per share	IBIO	The Nasdaq Stock Market LLC

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

​

​

​

​

Item 7.01. Regulation FD Disclosure.

​

iBio, Inc. (the “Company”) has updated its corporate presentation. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K.

​

The corporate presentation attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

​

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

​

Item 8.01. Other Events.

​

The Company has updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

​

​

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K.

Exhibit Number		Exhibit Description
99.1	​	Corporate Presentation of iBio, Inc., dated November 2025
104	​	Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​	​	​	​
Date: November 17, 2025	IBIO, INC.
​	By:	/s/ Marc A. Banjak
		Name:	Marc A. Banjak
​	​	Title:	Chief Legal Officer

​

​

​

FAQ

What did iBio (IBIO) announce in its November 2025 Form 8-K?

iBio reported that it has updated its corporate presentation and is furnishing the revised investor materials as Exhibit 99.1 to the Form 8-K.

What is Exhibit 99.1 in iBios November 2025 Form 8-K?

Exhibit 99.1 is the updated corporate presentation of iBio, Inc., dated November 2025, prepared for use in meetings with investors, analysts and others.

Why did iBio update its corporate presentation?

iBio states that it updated its corporate presentation for use in meetings with investors, analysts and others, and is making it publicly available by furnishing it as Exhibit 99.1.

Does the iBio corporate presentation include forward-looking statements?

Yes. The corporate presentation attached as Exhibit 99.1 includes safe harbor language indicating that certain statements are forward-looking rather than historical.

Is iBio obligated to update the information in the new presentation?

iBio states it has no duty or obligation to update or revise the information in the presentation, though it may do so through future SEC reports, press releases or other public disclosures.

What sections of the Form 8-K cover the updated iBio presentation?

The updated corporate presentation is discussed under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and is listed in Item 9.01 (Financial Statements and Exhibits) as Exhibit 99.1.